AVGR - Avinger, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1300
0.0000 (0.00%)
At close: 4:00PM EDT

1.1700 +0.04 (3.54%)
After hours: 5:16PM EDT

Stock chart is not supported by your current browser
Previous Close1.1300
Open1.1600
Bid1.1000 x 900
Ask1.1500 x 1400
Day's Range1.1400 - 1.1632
52 Week Range1.0600 - 16.5000
Volume402,930
Avg. Volume314,448
Market Cap7.26M
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)-7.0200
Earnings DateMay 4, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures.

  • GlobeNewswire

    Avinger Announces Proposed Underwritten Public Offering of Common Stock

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures.

  • ACCESSWIRE

    Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference

    REDWOOD, CA / ACCESSWIRE / August 19, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the Company’s Lumivascular technology at the annual AMP (Amputation Prevention Symposium) conference occurring last week.

  • Thomson Reuters StreetEvents

    Edited Transcript of AVGR earnings conference call or presentation 31-Jul-19 8:30pm GMT

    Q2 2019 Avinger Inc Earnings Call

  • GlobeNewswire

    Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019

    Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a.

  • GlobeNewswire

    Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States

    Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with the Pantheris SV (Small Vessel) image-guided atherectomy system. Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for the treatment of PAD and increases the number of addressable procedures for the Company’s Lumivascular technology by allowing physicians to target more distal regions of the vasculature in small diameter vessels.

  • GlobeNewswire

    Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019

    REDWOOD CITY, Calif., July 26, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided,.

  • ACCESSWIRE

    Avinger Announces Presentations by Key Opinion Leaders at CVC 2019

    REDWOOD CITY, CA / ACCESSWIRE / July 16, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced five podium presentations and a live case featuring the Company’s Lumivascular technology at the annual CVC conference occurring last week.

  • ACCESSWIRE

    Avinger Enrolls First 50 Patients in INSIGHT Clinical Trial

    REDWOOD CITY, CA / ACCESSWIRE / July 10, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the 50th patient enrolled in its INSIGHT clinical trial. The INSIGHT trial is a prospective, global, single arm, multi-center study to evaluate the safety and effectiveness of the Pantheris® Lumivascular atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. Dr. Jaafer Golzar, Avinger’s Chief Medical Officer and a highly experienced interventionalist, noted, “We are pleased to have the first 50 cases completed as part of our INSIGHT IDE study.

  • ACCESSWIRE

    Avinger Announces Commercial Launch of Ocelot in Australia

    REDWOOD, CA / ACCESSWIRE / July 8, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Ocelot image-guided chronic total occlusion (CTO) crossing system in Australia. As part of the Company’s exclusive distribution agreement with Diverse Devices Pty Ltd. for Avinger’s proprietary Lumivascular products in Australia, Ocelot completed the registration process with the Therapeutic Goods Administration (TGA) and is included on the Australian Register of Therapeutic Goods, which permits distribution in Australia.

  • GlobeNewswire

    Avinger to Effect One-for-Ten Reverse Stock Split

    Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Friday, June 21, 2019. As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock.

  • ACCESSWIRE

    Avinger Announces Distribution Agreement for Hong Kong

    REDWOOD CITY, CA / ACCESSWIRE / June 4, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has entered into an exclusive distribution agreement with Integmed Ltd. for the sales and marketing of Avinger's Lumivascular products in Hong Kong. Initial product shipments are anticipated during the current quarter and first patient treatments in Hong Kong are expected to commence in the third quarter of 2019. Integmed is a leading distributor of medical devices in Hong Kong for the treatment of cardiovascular disease, including a portfolio of complementary products for the endovascular treatment of arterial disease.

  • ACCESSWIRE

    Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference

    REDWOOD CITY, CA / ACCESSWIRE / May 30, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...

  • Is Avinger (AVGR) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Avinger (AVGR) Stock Outpacing Its Medical Peers This Year?

    Is (AVGR) Outperforming Other Medical Stocks This Year?

  • ACCESSWIRE

    Avinger Announces Successful Treatment of 1,000th Patient with Next-Generation Pantheris Device

    REDWOOD CITY, CA / ACCESSWIRE / May 16, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that physicians in 78 clinical sites have successfully treated more than 1,000 patients with the next-generation Pantheris image-guided atherectomy system. The next-generation Pantheris was launched on a limited basis in the U.S. following receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) in late May 2018 and features a number of improvements intended to augment the performance and reliability of the product. Importantly, clinical results have remained consistently positive in a variety of lesion types since market launch.

  • Thomson Reuters StreetEvents

    Edited Transcript of AVGR earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Avinger Inc Earnings Call

  • Associated Press

    Avinger: 1Q Earnings Snapshot

    The Redwood City, California-based company said it had a loss of 14 cents per share. The medical device maker posted revenue of $1.8 million in the period. In the final minutes of trading on Wednesday, ...

  • GlobeNewswire

    Avinger Provides First Quarter 2019 Shareholder Update

    REDWOOD CITY, Calif., May 08, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided,.

  • ACCESSWIRE

    Avinger, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Avinger, Inc. (NASDAQ: AVGR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. ...

  • Is Avinger (AVGR) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Avinger (AVGR) Outperforming Other Medical Stocks This Year?

    Is (AVGR) Outperforming Other Medical Stocks This Year?

  • Avinger (AVGR) Dips More Than Broader Markets: What You Should Know
    Zacks

    Avinger (AVGR) Dips More Than Broader Markets: What You Should Know

    Avinger (AVGR) closed at $0.58 in the latest trading session, marking a -0.62% move from the prior day.

  • ACCESSWIRE

    Avinger to Announce First Quarter 2019 Financial Results on May 8, 2019

    REDWOOD CITY, CA / ACCESSWIRE / May 2, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...

  • ACCESSWIRE

    Avinger Announces Issuance of New U.S. Patent and Receives Notice of Allowance for Five Additional U.S. Patents

    Extensive Intellectual Property Portfolio Now Includes 149 Patents and Applications REDWOOD CITY, CA / ACCESSWIRE / April 17, 2019 / Avinger, Inc. (NASDAQ: AVGR ), a leading developer of image-guided, ...

  • ACCESSWIRE

    Avinger Announces Publication of Study Demonstrating Positive Clinical Outcomes for Patients Treated with Pantheris Prior to Antirestenotic Therapy

    REDWOOD CITY, CA / ACCESSWIRE / April 15, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the publication of very promising clinical outcomes data from a study evaluating the performance of the Pantheris® Lumivascular atherectomy system combined with antirestenotic therapy in the treatment of PAD. The study analyzed the clinical outcomes of 33 patients (37 lesions) with symptomatic peripheral arterial disease treated by OCT-guided atherectomy with Pantheris prior to application of a drug-coated balloon.

  • Top Ranked Momentum Stocks to Buy for April 11th
    Zacks

    Top Ranked Momentum Stocks to Buy for April 11th

    Top Ranked Momentum Stocks to Buy for April 11th